GlassScriptPhysician profile
Anthony J Kalliath
NPI 1902989189
$901.93
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $103 · 2021: $313 · 2022: $42.95 · 2023: $34.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $163.00 | 2019-2021 | |
| Amgen INC. | $100.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $79.69 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $63.92 | 2021-2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $63.22 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $58.75 | 2019 | |
| Stemline Therapeutics INC. | $58.75 | 2019 | |
| Tesaro, INC. | $48.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $43.77 | 2019-2021 | |
| Incyte Corporation | $42.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.51 | 2020-2021 | |
| Genzyme Corporation | $32.13 | 2020-2021 | |
| Kite Pharma, INC. | $28.90 | 2022 | |
| Eisai INC. | $25.70 | 2021 | |
| Janssen Biotech, INC. | $23.00 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.88 | 2021 | |
| Seagen INC. | $13.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Kalliath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.